Zobrazeno 1 - 10
of 514
pro vyhledávání: '"Messoud Ashina"'
Autor:
Song Guo, Rikke Holm Rasmussen, Anders Hay-Schmidt, Messoud Ashina, Ayodeji A. Asuni, Jeppe Møller Jensen, Anja Holm, Sabrina Prehn Lauritzen, Glenn Dorsam, Jens Hannibal, Birgitte Georg, David Møbjerg Kristensen, Jes Olesen, Sarah Louise Christensen
Publikováno v:
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-12 (2024)
Abstract Background Pituitary adenylate cyclase-activating peptide (PACAP) is a neuropeptide pivotal in migraine pathophysiology and is considered a promising new migraine drug target. Although intravenous PACAP triggers migraine attacks and a recent
Externí odkaz:
https://doaj.org/article/1b5638b4204d4c57a3832603fc0281f0
Autor:
Haidar M. Al-Khazali, Rune H. Christensen, Basit Ali Chaudhry, Anna G. Melchior, Messoud Ashina, Rami Burstein, Håkan Ashina
Publikováno v:
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-10 (2024)
Abstract Background Phosphodiesterase 3 (PDE-3) inhibition have been implicated in the neurobiologic underpinnings of migraine. Considering the clinical similarities between migraine and persistent post-traumatic headache (PPTH), we aimed to ascertai
Externí odkaz:
https://doaj.org/article/a5c08303212347fda4114fc6350cfcd8
Autor:
Paul Rizzoli, Michael J. Marmura, Jennifer Robblee, Jennifer McVige, Sara Sacco, Stephanie J. Nahas, Jessica Ailani, Rosa De Abreu Ferreira, Julia Ma, Jonathan H. Smith, Brett Dabruzzo, Messoud Ashina
Publikováno v:
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-10 (2024)
Abstract Background Conventional, non-specific preventive migraine treatments often demonstrate low rates of treatment persistence due to poor efficacy or tolerability. Effective, well-tolerated preventive treatments are needed to reduce migraine sym
Externí odkaz:
https://doaj.org/article/04ca5a47ea8141e181232ded6eeb22d4
Autor:
Andreas Vinther Thomsen, Håkan Ashina, Haidar M. Al-Khazali, Kathrine Rose, Rune Häckert Christensen, Faisal Mohammad Amin, Messoud Ashina
Publikováno v:
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-10 (2024)
Abstract Background About one-third of persons with migraine experience transient neurologic symptoms, referred to as aura. Despite its widespread prevalence, comprehensive clinical descriptions of migraine with aura remain sparse. Therefore, we aime
Externí odkaz:
https://doaj.org/article/ab7f16aa46924e0188343cf4347f25cc
Autor:
Janu Thuraiaiyah, Håkan Ashina, Rune Häckert Christensen, Haidar M. Al-Khazali, Messoud Ashina
Publikováno v:
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-11 (2024)
Abstract Background Migraine is a multiphasic neurovascular disorder, where headache can be succeeded by postdromal symptoms. However, there are limited research on postdromal symptoms. This study aimed to investigate the proportion of individuals wi
Externí odkaz:
https://doaj.org/article/11106cb5eab7437e8be0d260d9ea777f
Autor:
Patricia Pozo-Rosich, Messoud Ashina, Stewart J. Tepper, Sidsel Jensen, Line Pickering Boserup, Mette Krog Josiassen, Bjørn Sperling
Publikováno v:
Neurology and Therapy, Vol 13, Iss 2, Pp 339-353 (2024)
Abstract Introduction In the DELIVER study, eptinezumab reduced monthly migraine days (MMDs) more than placebo in patients with 2–4 prior preventive migraine treatment failures. This post hoc analysis evaluated the efficacy of eptinezumab across th
Externí odkaz:
https://doaj.org/article/db3613d3bbe843fc9dda99c7098d8dd2
Autor:
Messoud Ashina, Stewart J. Tepper, Astrid Gendolla, Bjørn Sperling, Anders Ettrup, Mette Krog Josiassen, Amaal J. Starling
Publikováno v:
The Journal of Headache and Pain, Vol 24, Iss 1, Pp 1-13 (2023)
Abstract Background Eptinezumab demonstrated efficacy in adults with migraine and prior preventive treatment failures in the placebo-controlled phase of the DELIVER clinical trial; its long-term effectiveness in this population has not yet been repor
Externí odkaz:
https://doaj.org/article/b734ea6886ea41c5ad098af8bbd3e973
Autor:
Paolo Martelletti, Matilde Leonardi, Messoud Ashina, Rami Burstein, Soo-Jin Cho, Augustina Charway-Felli, David W. Dodick, Raquel Gil-Gouveia, Licia Grazzi, Christian Lampl, Antoinette MaassenVanDenBrink, Mia T. Minen, Dimos Dimitrios Mitsikostas, Jes Olesen, Mayowa Ojo Owolabi, Uwe Reuter, Elena Ruiz de la Torre, Simona Sacco, Todd J Schwedt, Gianluca Serafini, Nirmal Surya, Cristina Tassorelli, Shuu-Jiun Wang, Yonggang Wang, Tissa Wijeratne, Alberto Raggi
Publikováno v:
The Journal of Headache and Pain, Vol 24, Iss 1, Pp 1-17 (2023)
Abstract The 2030 Agenda for Sustainable Development sets out, through 17 Sustainable Development Goals (SDGs), a path for the prosperity of people and the planet. SDG 3 in particular aims to ensure healthy lives and promote well-being for all at all
Externí odkaz:
https://doaj.org/article/9767ef7494b74f529cd62eb1844039fa
Autor:
Bianca Raffaelli, Thien Phu Do, Basit Ali Chaudhry, Messoud Ashina, Faisal Mohammad Amin, Håkan Ashina
Publikováno v:
The Journal of Headache and Pain, Vol 24, Iss 1, Pp 1-10 (2023)
Abstract Objective To explore and critically appraise the evidence supporting the role of estrogen withdrawal in menstrual migraine. Main body Menstrual migraine, impacting about 6% of reproductive-age women, manifests as migraine attacks closely rel
Externí odkaz:
https://doaj.org/article/97efc1ebc6d54f3ebe2ac44eceea98fb
Autor:
Haidar M. Al-Khazali, Håkan Ashina, Astrid Wiggers, Kathrine Rose, Afrim Iljazi, Rune Häckert Christensen, Henrik Winther Schytz, Faisal Mohammad Amin, Messoud Ashina
Publikováno v:
The Journal of Headache and Pain, Vol 24, Iss 1, Pp 1-14 (2023)
Abstract Background Although the involvement of calcitonin gene-related peptide (CGRP) in migraines is well-established, its specific role in investigating the aura phase, which often precedes the headache, remains largely unexplored. This study aims
Externí odkaz:
https://doaj.org/article/37207a06e1d24e57adbc6bf31c95b7e4